Alvea is a biotechnology company dedicated to deploying medical countermeasures that fight infectious diseases. We are developing new vaccines against SARS-CoV-2 and its variants as step one in a plan to strengthen humanity against future biological threats.
Our Mission /
To Build a Platform for Pandemic Response as Global, Flexible, and Fast as the Pathogens we Face.
We’re a team of drug designers, clinical development experts, physicians, and operators dedicated to deploying novel medical countermeasures for use against pandemics.
We build simple, scalable, and shelf-stable medicines and prophylactics appropriate for use anywhere that humans call home.
Leadership /
Backed By /
Careers /
The threat from new pathogens has never been greater. We need motivated, fast-moving people with a broad range of backgrounds and specialties.
If you think you’d be a good fit, or you want to hear more about opportunities at Alvea, please get in touch.
Latest News /
Alvea Set the Record for Fastest Startup to Take a New Drug into a Phase 1 Clinical Trial, from Founding to First-in-Human
From Founding to Protecting Patients in 28 Weeks After reviewing every Phase 1 clinical trial in the last 35 years, we found that our time from startup formation to first patient dosing (196 days) was faster than any other startup on record has ever taken a new drug into the clinic. Alvea’s plasmid DNA Omicron […]
Lessons from Developing a COVID Vaccine
Alvea’s CEO, Grigory Khimulya, reflects on lessons from the first six months of Alvea’s effort to bring a shelf-stable COVID-19 Omicron vaccine from idea to patients. He discusses inefficiencies in the clinical development process, what make’s Alvea’s culture and approach to clinical development different, and takes questions from the audience on a range of topics.
Alvea Launches Scalable, Shelf- Stable DNA Vaccine Development against New SARS-CoV-2 Variants 2
Breakthrough DNA vaccine, Alveavax, enters pre-clinical testing for Omicron & BA.2 variants. Alvea, a startup biotechnology company, today announced that it will begin to develop, test, and deliver DNA vaccines at scale to low and middle income countries with limited access to existing vaccine options.